HERPES VIRUS SURVEILLANCE IN PEDIATRIC SOLID ORGAN TRANSPLANT RECIPIENTS

儿科实体器官移植受者的疱疹病毒监测

• 批准号: 7379392
• 负责人: Jodi M Smith
• 金额: $ 1.57万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379392
• 关键词: HERPES; VIRUS; SURVEILLANCE; PEDIATRIC; SOLID

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Viral infections are an important complication of transplantation. Immunosuppressive therapy interferes with T cell immunity resulting in a high incidence of viral infection. Newer agents, such as mycophenolate mofetil (MMF) and sirolimus, have been associated with an increased risk of herpes virus infection. The introduction of these more potent immunosuppressive agents over the past decade correlates with an increase in the rate of hospitalizations of transplant patients with infections. This prospective study will determine the role of subclinical herpes virus infections in the development of complications such as chronic allograft nephropathy (CAN) and PTLD. By focusing on treatable herpes virus infections, these studies have the potential to identify therapeutic strategies that can be used to diminish the burden of graft loss from CAN, significantly improving renal allograft survival and quality of life in transplant patients. Future specific interventions to test the hypothesis of a direct causal relationship between subclinical herpes virus infection and CAN may include the use of anti-viral therapy in response to subclinical infection of the renal allograft and / or peripheral blood.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。病毒感染是移植的重要并发症。免疫抑制治疗会干扰 T 细胞免疫，导致病毒感染的高发生率。霉酚酸酯 (MMF) 和西罗莫司等新型药物与疱疹病毒感染风险增加有关。过去十年中这些更有效的免疫抑制剂的引入与移植患者感染住院率的增加相关。这项前瞻性研究将确定亚临床疱疹病毒感染在慢性同种异体移植肾病 (CAN) 和 PTLD 等并发症发展中的作用。通过关注可治疗的疱疹病毒感染，这些研究有可能确定可用于减轻 CAN 移植物损失负担的治疗策略，从而显着提高肾同种异体移植物的存活率和移植患者的生活质量。未来检验亚临床疱疹病毒感染与 CAN 之间直接因果关系假设的具体干预措施可能包括使用抗病毒治疗来应对同种异体肾和/或外周血的亚临床感染。